Gerresheimer has agreed to sell two of its packaging units—Centor US Holding, which specializes in packaging systems for dispensing prescription drugs, and its global primary packaging plastics business—to an affiliate of funds advised by Apax Partners, a private equity firm, for EUR 1.5 billion ($1.7 billion).  

In 2025, the two businesses generated combined revenue of approximately EUR 570 million ($657 million) with a combined number of employees of approximately 2,400. The Centor facility is in Millersburg, Ohio, where the company manufactures packaging systems for prescription drug dispensing, including vials, plastic bottles, and closures. In addition to the Centor site in the US, the transaction includes a total of 15 production sites for primary plastic packaging in nine countries. 

“This transaction allows us to regain our strategic flexibility,” explains Uwe Röhrhoff, CEO of Gerresheimer AG, in a July 29, 2026, statement in announcing the sale. “At the same time, as a leading global partner to the pharmaceutical and biotech industries, we are focusing our business even more strongly on high-value drug delivery and medical devices and primary packaging for injectable drugs.” 

The purchase price for the two business units combined is based on an enterprise value of approximately EUR 1.5 billion ($1.7 billion). The parties have agreed not to disclose further terms of the agreements. The transactions are subject to customary closing conditions and approvals and will be closed independently of one another. The sale of Centor is expected to close by the end of financial year 2026, and the sale of the global primary packaging plastics business is expected to close in the first half of financial year 2027. 

Source: Gerresheimer